The metabolic syndrome and development of cognitive impairment among older women

Archives of Neurology

Volumn 66, Issue 3, 2009, Pages 324-328

  Yaffe, Kristine ^a,b,c   Weston, Andrea L ^a,c   Blackwell, Terri ^d   Krueger, Kathryn A ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE;

AGED; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; COGNITION DISORDERS; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; LONGITUDINAL STUDIES; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 62449313661     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2008.566     Document Type: Article

References (36)

1. Ott A, Breteler MM, van Harskamp F, Stijnen T, Hofman A. Incidence and risk of dementia: the Rotterdam Study. Am J Epidemiol. 1998;147(6):574-580.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119-1122.
3. Knopman D, Boland LL, Mosley T, et al; Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56(1):42-48.
4. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging. 2000;21(1):49-55.
5. Hayden KM, Zandi PP, Lyketsos CG, et al; Cache County Investigators. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County Study. Alzheimer Dis Assoc Disord. 2006;20(2):93-100.
6. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005; 62(10):1556-1560.
7. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59(3):378-384.
8. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330(7504):1360-1365.
9. Akomolafe A, Beiser A, Meigs JB, et al. Diabetes mellitus and risk of developing Alzheimer disease. Arch Neurol. 2006;63(11):1551-1555.
10. Yaffe K, Blackwell TL, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology. 2004;63(4):658-663.
11. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4(2):147-152.
12. Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287(3):356-359.
14. Muller M, Ming-Xin Tang H, Schupf HN, Manly JJ, Mayeux R, Luchsinger JA. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord. 2007;24(3):185-192.
15. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol. 2007;64(1):93-96.
16. van den Berg E, Biessels GJ, de Craen AJM, Gussekloo J, Westendorp RGJ. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology. 2007;69(10):979-985.
17. Vanhanen M, Koivisto K, Moilanen L, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology. 2006;67(5):843-847.
18. Yaffe K, Haan MN, Blackwell TL, Cherkasova E, Whitmer RA, West N. Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of Aging Study. J Am Geriatr Soc. 2007;55(5):758-762.
19. Yaffe K, Kanaya AM, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292(18):2237- 2242.
20. Yaffe K. Metabolic syndrome and cognitive disorders: is the sum greater than its parts? Alzheimer Dis Assoc Disord. 2007;21(2):167-171.
21. Ettinger B, Black DM, Mitlak BH, et al; Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282(7):637-645.
22. Sheikh J, Yesavage J. Geriatric Depression Scale: recent evidence and development of a shorter version. In: TL Brink, ed. Clinical Gerontologist. New York: The Haworth Press; 1986;5:165-173.
23. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry. 2005;162 (4):683-690.
24. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983;140(6):734-739.
25. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34(7):939-944.
27. Blessed G, Tomlinson BE, Roth M. Blessed-Roth Dementia Scale (DS). Psychopharmacol Bull. 1988;24(4):705-708.
28. Lawlor DA, Ebrahim S, Davey Smith G. The metabolic syndrome and coronary heart disease in older women: findings from the British Women's Heart and Health Study. Diabet Med. 2004;21(8):906-913.
29. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men: the Honolulu-Asia Aging Study. Arterioscler Thromb Vasc Biol. 2000;20(10):2255-2260.
30. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev. 2002;1(1):61-77.
31. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487-499.
32. Gasparini L, Gouras GK, Wang R, et al. Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneuronal β-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 2001;21(8):2561-2570.
33. Jagust W, Harvey D, Mungas D, Haan MN. Central obesity and the aging brain. Arch Neurol. 2005;62(10):1545-1548.
34. Dik MG, Jokner C, Comijs HC, et al. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care. 2007;30(10):2655-2660.
35. Asomaning K, Bertone-Johnson ER, Nasca PC, Hooven F, Pekow PS. The association between body mass index and osteoporosis in patients referred for a bone mineral density examination. J Womens Health (Larchmt). 2006;15(9):1028-1034.
36. Dalton M, Cameron AJ, Zimmet PZ, et al; AusDiab Steering Committee. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med. 2003;254(6):555-563.